Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. A 26-week, randomised, double-blind, placebo-controlled trial
Phase of Trial: Phase III
Latest Information Update: 13 Jan 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 1 - Monotherapy
- Sponsors Novo Nordisk
- 12 Dec 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.
- 10 Jun 2017 Biomarkers information updated